Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P M Bhende
The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Nab-Paclitaxel Antitumor Response in Experimental Gastric Cancer
International Journal of Oncology
Cancer Research
Oncology
Efficacy of the Dual PI3K and mTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate Against Chronic Myelogenous Leukemia Cell Lines
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
NVP-BEZ235, a Novel Dual PI3K/mTOR Inhibitor, Enhances the Radiosensitivity of Human Glioma Stem Cells in Vitro
Acta Pharmacologica Sinica
Medicine
Pharmacology
Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines Under Normoxic and Hypoxic Conditions
Breast Cancer: Basic and Clinical Research
Cancer Research
Oncology
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Clinical Cancer Research
Cancer Research
Oncology
Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
Cancer Research
Cancer Research
Oncology
Progress Against Follicular Lymphoma
Current Opinion in Hematology
Hematology
